CheckMate 577 Final Results: Adjuvant Nivolumab Sustains Disease-Free Survival Benefit in Resected Esophageal and Gastroesophageal Junction Cancer

CheckMate 577 Final Results: Adjuvant Nivolumab Sustains Disease-Free Survival Benefit in Resected Esophageal and Gastroesophageal Junction Cancer

CheckMate 577 Final Results: Adjuvant Nivolumab Sustains Disease-Free Survival Benefit in Resected Esophageal and Gastroesophageal Junction Cancer

CheckMate 577 Final Results: Adjuvant Nivolumab Sustains Disease-Free Survival Benefit in Resected Esophageal and Gastroesophageal Junction Cancer

CheckMate 577 Final Results: Adjuvant Nivolumab Sustains Disease-Free Survival Benefit in Resected Esophageal and Gastroesophageal Junction Cancer

CheckMate 577 Final Results: Adjuvant Nivolumab Sustains Disease-Free Survival Benefit in Resected Esophageal and Gastroesophageal Junction Cancer

CheckMate 577 Final Results: Adjuvant Nivolumab Sustains Disease-Free Survival Benefit in Resected Esophageal and Gastroesophageal Junction Cancer

CheckMate 577 Final Results: Adjuvant Nivolumab Sustains Disease-Free Survival Benefit in Resected Esophageal and Gastroesophageal Junction Cancer

gastroesophageal junction